MarketCap
Facebook
X
TelegramAdamas Pharmaceuticals, Inc. Langfristige Verbindlichkeiten 2011-2026 | ADMS
Langfristige Verbindlichkeiten Jährlich Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 135 M | 136 M | 121 M | 103 M | 547 K | 749 K | 1.57 M | 12 K | 20.9 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 136 M | 12 K | 57.7 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
15 M | $ 8.79 | 0.8 % | $ 86.9 M |  USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
332 | $ 3.23 | 3.7 % | $ 275 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
341 M | $ 97.22 | 0.54 % | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.21 | 0.16 % | $ 323 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 21.3 | -0.3 % | $ 996 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
4.72 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 1.51 | 2.59 % | $ 388 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.15 | 7.87 % | $ 5.19 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.2 | 0.24 % | $ 449 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 25.08 | 3.96 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
196 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Evogene Ltd.
EVGN
|
5.36 M | $ 0.82 | -0.07 % | $ 27.9 M | Israel |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 32.73 | 0.43 % | $ 2.17 B | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 32.72 | 6.91 % | $ 424 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.49 | 1.27 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
942 K | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |